RE:I Thought The 100 people where pickedGonefishing2022,
If they get BTD, then they'll be looking for the AA to follow. AA gives them the ability to begin charging patients for the costs of the treatment, including the remaining trial patients. That brings in money, but also makes the treatment more attractive to potential partners, whether for licensing, joint venture, or buy out options. More desirability = higher stock price.
I doubt the additional 37 trial patients have all been identified yet. What made you think they had been? It's the job of each trial site to recruit and select the trial patients. Theralase is not directly involved as either the recruiter or the selector. They just provide the funding for the trials. The enrollment processing time is nominally a couple months as the patient histories are gathered, screened, and scrutinized for eligibility for enrollment for the trial. Sometimes life simply gets in the way. More often, a potential patient is screened out of enrollment for failure to meet the eligibility criteria.
Since he hasn't been able to attract a deep-pocketed partner or three, RDW is committed to bringing this through the clinical trial process on a shoestring budget. Hence, the need for frequent money raises to date.
Note: I'm not a rocket scientist, just a rocket engineer with some additional laser experience. I'm well into my second decade here.